Clinical Trial: Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07916376) titled 'Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response' on Oct. 29.

Brief Summary: The purpose of this study is to find out whether a special type of magnetic resonance imaging ( MRI), called blood oxygen level-dependent (BOLD) MRI, can help measure how much oxygen is present in liver tumors. Tumors with low oxygen levels are described as being hypoxic.

Yttrium-90 (Y-90) is a type of radioactive material used to treat liver tumors, including hepatocellular carcinoma (HCC), a type of liver cancer. Y-90 is a form of radiation treatment delivered directly to liver tumors through tiny beads carried by blood vessel...